| Trial ID: | L2972 |
| Source ID: | NCT01753362
|
| Associated Drug: |
Liraglutide
|
| Title: |
Liraglutide In Overweight Patients With Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01753362/results
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: liraglutide|DRUG: placebo
|
| Outcome Measures: |
Primary: HbA1c, The primary endpoint of the study is to detect a difference in HbA1c percent at baseline and after 26 weeks of treatment with Liraglutide or placebo., 26 weeks | Secondary: Glucose Concentrations, Mean daily glucose concentrations at baseline and 26 weeks, 26 weeks
|
| Sponsor/Collaborators: |
Sponsor: University at Buffalo | Collaborators: Juvenile Diabetes Research Foundation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
84
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-12
|
| Completion Date: |
2018-02
|
| Results First Posted: |
2019-12-17
|
| Last Update Posted: |
2019-12-17
|
| Locations: |
diabetes endocrinology center of WNY, Buffalo, New York, 14215, United States|Diabetes Endocrinology Research Center of WNY, Buffalo, New York, 14215, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01753362
|
